Prevalence and natural course of gastroesophageal reflux disease

被引：12
作者：
Labenz J. [1 ]
Labenz C. [2 ]
机构：
[1] Diakonie Klinikum – Jung-Stilling-Krankenhaus, Wichernstr. 40, Siegen
[2] Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Essen
来源：
Der Gastroenterologe | 2016年 / 11卷 / 2期
关键词：
Barrett‘s carcinoma; Barrett‘s esophagus; Endoskopy; Epidemiology; Gastroesophageal reflux disease;
D O I：
10.1007/s11377-016-0045-0
中图分类号：
学科分类号：
摘要：
Background: The epidemiology of a disease, in particular the natural course, is important for treatment planning and monitoring strategies. Objective: Incidence, prevalence, and natural course of gastroesophageal reflux disease (GERD). Materials and methods: Selective literature search in the database PubMed. Results: In industrialized countries, approximately 20 % of adults suffer from symptomatic GERD. In addition, asymptomatic esophageal reflux and Barrett esophagus was observed in more than 5 % of the general public in an endoscopic population based study. Spontaneous healing of GERD does occur, but in the majority of cases the disease is chronic. GERD is not a categorical disease. Approximately 25–30 % of patients have endoscopic progression of their disease over time. The cancer risk of Barrett esophagus is estimated to be 0.1–0.15 % per year, which is less than originally assumed. Overall, GERD is not associated with a shortened life expectancy. The epidemiology of extra-esophageal symptoms is largely unknown. Conclusion: GERD is a common disease with a good prognosis with regard to survival. Spontaneous recovery occurs as well as progression of endoscopic lesions. The cancer risk of Barrett esophagus is lower than expected; thus, surveillance should be limited to high-risk patients. © 2016, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码：102 / 109
页数：7
相关论文
共 44 条
  • [11] Haag S., Andrews J.M., Gapasin J., Et al., A 13-nation population survey of upper gastrointestinal symptoms: prevalence of symptoms and socioeconomic factors, Aliment Pharmacol Ther, 33, pp. 722-729, (2011)
  • [12] Hampel H., Abraham N.S., El-Serag H.B., Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications, Ann Intern Med, 143, pp. 199-211, (2005)
  • [13] Hvid-Jensen F., Pedersen L., Drewes A.M., Et al., Incidence of adenocarcinoma among patients with Barrett´s esophagus, N Engl J Med, 365, pp. 1375-1383, (2011)
  • [14] Jaspersen D., Kulig M., Labenz J., Et al., Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD study, Aliment Pharmacol Ther, 17, pp. 1515-1520, (2003)
  • [15] Johnson D.A., Fennerty M.B., Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease, Gastroenterology, 126, 3, pp. 660-664, (2004)
  • [16] Kay L., Jorgensen T., Jensen K.H., Epidemiology of abdominal symptoms in a random population: prevalence, incidence, and natural history, Eur J Epidemiol, 10, pp. 559-566, (1994)
  • [17] Koop H., Fuchs K.H., Labenz J., Et al., S2k-Leitlinie: Gastroösophageale Refluxkrankheit unter Federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Z Gastroenterol, 52, pp. 1299-1346, (2014)
  • [18] Labenz J., Jaspersen D., Kulig M., Et al., Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative, Am J Gastroenterol, 99, pp. 1652-1656, (2004)
  • [19] Labenz J., Nocon M., Lind T., Et al., Prospective follow-up data from the ProGERD study suggests that GERD is not a categorial disease, Am J Gastroenterol, 101, pp. 2457-2462, (2006)
  • [20] Labenz J., Koop H., Tannapfel A., Et al., The epidemiology, diagnosis and treatment of Barrett carcinoma, Dtsch Arztebl Int, 112, pp. 224-234, (2015)
12345